The Dish’s Weekly Biotechnology News Wrap Up – December 1, 2017
This week’s headlines include: Gene Therapy Hits a Peculiar Roadblock: A Virus Shortage, Takeda pushes U.S.-backed Zika vaccine into the clinic, GE Healthcare Acquires UK’s Puridify, GSK, MMV submit malaria drug in the US, FDA backs Roche’s Gazyva in first-line follicular lymphoma, and bluebird bio Acquires Durham, NC, Manufacturing Site for Lentiviral Vector Production.
In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:
Ask the Expert – Enabling Stem Cell Therapy Biomanufacturing using Dissolvable Microcarriers
Cell culture on microcarriers is an increasingly important technique for the production of large cell quantities and the scale-up of Cell Therapy applications. Microcarriers—small, spherical beads used to grow adherent cells in a suspension culture—offer several advantages for large-scale cell culture: Because they are suspended, microcarriers allow for a maximized surface area-to-volume ratio. Single-vessel conditions make microcarriers amenable to scale-up applications. Microcarriers also offer the ability to monitor and control physiological conditions when used in bioreactors…Organoid Cell Culture – Frequently Asked Questions
We recently finished our Ask the Expert discussion, “Going tiny is the next BIG thing: Tools and Techniques for Organoid Cultures”. During this Ask the Expert session, we covered topics related to the culture of organoids including, media requirements, co-culture with other cells, surface requirements, culture vessels, nutrient delivery and gas exchange, harvesting organoids, and key points on the cell culture process timeline. In addition, we also had questions about making organoid cell culture more high throughput to meet the needs of drug screening, the difference between spheroids and organoids, and best practices for immunostaining of organoids…Video – Upstream Bioprocessing Cell Culture Overview
An overview of upstream bioprocessing steps beginning with an explanation of molecular biology and cell line engineering, then continuing with creation of a working cell bank, cell expansion, bioreactor production and clarification steps…FBS – It’s not all created equal – what consumers need to know
In this podcast and accompanying article, we interviewed Alyssa Master, Ph.D., Senior Manager of Science and Applications, Nucleus Biologics about some of the challenges of working with FBS, why not all FBS is created equal and suggestions for FBS customers who are trying to navigate these issues…
